Sarepta is a biopharmaceutical company focused on the discovery and development of therapeutics for the treatment of rare, infectious and other diseases. The Company developed the drug eteplirsen for the treatment of Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease. Eteplirsen is designed to increase the underlying cause of DMD by enabling production of the protein dystrophin.
On this news, the price of Sarepta common stock plummeted more than 54%, from
What You Can Do
If you purchased Sarepta stock between
About Scott+Scott, Attorneys at
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scottscott-attorneys-at-law-llp-reminds-investors-of-its-investigation-of-sarepta-therapeutics-inc-srpt-300440995.html
SOURCE Scott+Scott, Attorneys at